HGH Fragment 176-191: Targeted Fat Loss

Category: Protocols Type: Protocol Read Time: 14 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/fragment-176-191-protocol

Educational content only. Not medical advice. Consult a licensed healthcare provider before starting any protocol.

Overview

HGH Fragment 176-191 is a synthetic peptide corresponding to the C-terminal 16-amino-acid region of human growth hormone (residues 176 through 191). Early researchers (Heffernan, Ng and colleagues) hypothesized that the lipolytic — fat-mobilizing — activity of hGH could be isolated from its growth-promoting and glucose-disrupting effects by replicating only this tail-end sequence.

The result is a fragment that, in preclinical studies, appeared to stimulate fat breakdown without measurable elevations in IGF-1 and without the insulin resistance commonly associated with supraphysiologic hGH dosing. This positioned Fragment 176-191 as a "targeted" lipolytic agent — conceptually related to AOD-9604 (which is a stabilized derivative of the same sequence) but structurally distinct in important ways.

Key Properties:

• 16 amino acids (raw C-terminal hGH fragment)
• No appreciable IGF-1 elevation in published animal data
• Did not impair glucose tolerance in early studies
• Designed for subcutaneous administration
• Not FDA-approved; sold as a research chemical
• WADA-prohibited substance for competitive athletes

Mechanism of Action

Fragment 176-191 is proposed to act primarily on adipocytes (fat cells) through the beta-3 adrenergic receptor pathway, which is a key driver of lipolysis in white and brown adipose tissue.

The proposed mechanisms include:

1. Beta-3 adrenergic stimulation — Increases cyclic AMP signaling in adipocytes, activating hormone-sensitive lipase
2. Lipolysis promotion — Triglycerides are mobilized from fat stores and released as free fatty acids
3. Lipogenesis inhibition — May reduce the conversion of incoming substrate into new triglycerides
4. Selective signaling — In animal models, did not significantly raise IGF-1 or growth-axis markers
5. Glucose neutrality — Early studies reported no meaningful disruption of fasting glucose or insulin sensitivity

Importantly, these mechanisms are derived largely from animal studies and small early-phase human trials. Long-term human pharmacodynamic data remain limited.

Frag 176-191 vs AOD-9604

This is the single most confused topic in this category. The two compounds are related but not identical.

Sourcing caveat: Because the sequences share a core, vendor labeling is inconsistent. A vial marked "HGH Fragment 176-191" may in practice be AOD-9604, and vice versa. Demand third-party COAs with mass spectrometry and HPLC purity for whichever you buy.

Dosing Protocols

Dosing in the community-research literature is empirical, not consensus-based. The ranges below reflect commonly reported subcutaneous protocols, not clinically validated regimens.

General principles:

• Subcutaneous injection into abdominal fat is most common
• Short half-life supports split dosing
• Many users front-load AM dose for fasted-cardio synergy
• Dose escalation should be gradual; there is no advantage to starting at the high end

Fasted Administration Protocol

Most community protocols pair Fragment 176-191 with a fasted morning window. The reasoning is mechanistic rather than clinical:

• Lipolytic context — Insulin is low, so fatty acids mobilized by the fragment are less likely to be re-esterified into storage
• No carb buffer — Eating raises insulin, which suppresses hormone-sensitive lipase activity
• Insulin-sensitive window — Morning insulin sensitivity supports preferential fat oxidation
• Fasted cardio synergy — Light-to-moderate steady-state cardio after dosing may enhance fatty acid utilization

Sample fasted morning protocol:

1. Wake; hydrate with water and electrolytes
2. Inject 250-500 mcg Fragment 176-191 subcutaneously
3. Wait 20-30 minutes
4. Perform 30-45 minutes of zone-2 cardio
5. Delay first meal by 60-90 minutes after cardio if tolerated

This protocol is anecdotal. There is no controlled trial demonstrating that fasted administration produces meaningfully different outcomes than fed administration in humans.

Expected Outcomes

Honest framing matters here. Fragment 176-191 is not a transformation agent.

Weeks 1-3:

• Subjective sense of warmth or mild thermogenesis after dosing (variable)
• No visible change
• Some users report appetite modulation; many report none

Weeks 4-8:

• Slow recomposition in subcutaneous fat, particularly abdominal
• Skinfold and tape measurements may show small reductions
• Scale changes typically minimal (1-3 lbs over the window)

Weeks 8-12:

• More visible subcutaneous reduction when paired with caloric deficit and training
• No appreciable muscle gain or loss attributable to the peptide
• Plateaus are common; this is not a continuous dose-response

The honest baseline: in users already running a caloric deficit and structured training, Fragment 176-191 may modestly accelerate fat loss. In users not running a deficit, results are typically negligible.

Side Effects & Safety

Fragment 176-191 is generally well-tolerated in short-term use. Reported side effects:

• Injection site reactions — Redness, mild swelling, or transient irritation
• Mild fatigue — More common at the 500 mcg twice-daily range
• Flushing or warmth — Transient, typically post-dose
• Headache — Uncommon
• Hunger fluctuations — Variable; some report suppression, others no change

Theoretical concerns:

• Long-term beta-3 adrenergic stimulation has not been studied in humans
• Effects on cardiovascular parameters at high chronic doses are unknown
• Interaction with other catecholaminergic compounds (stimulants, clenbuterol-class agents) is not well characterized

Contraindications:

• Pregnancy or breastfeeding
• Active cardiovascular disease without medical supervision
• Concurrent use of stimulant fat-loss agents without provider input
• Competitive athletes subject to WADA testing

Stacking

Fragment 176-191 stacks logically with compounds that act on independent pathways.

With GH-axis support (CJC-1295 + Ipamorelin)

• Rationale: GHRH/GHRP combinations raise endogenous pulsatile GH and IGF-1 modestly; Fragment 176-191 provides direct lipolytic signaling
• Typical pattern: CJC-1295 + Ipamorelin nightly; Fragment 176-191 fasted AM
• Note: this stack is more about complementary signaling than additive fat loss

With GLP-1 receptor agonists (semaglutide, tirzepatide)

• Rationale: GLP-1s reduce caloric intake via appetite suppression and gastric emptying; Fragment 176-191 acts on lipolysis directly
• Layered effect: the deficit is driven by the GLP-1; the fragment may marginally accelerate fat mobilization within that deficit
• Coordinate with your prescriber — these are different regulatory categories

With caloric deficit and cardio (essential foundation)

• No peptide substitutes for energy balance
• Fragment 176-191 amplifies, it does not replace
• Pair with 300-500 kcal/day deficit and 3-5 cardio sessions weekly for any reasonable expectation of result

Cycling

Most users run Fragment 176-191 in 8-12 week blocks with a 4-8 week washout. The rationale is empirical — there is no firm pharmacological reason for these intervals, but it limits unknown long-term receptor adaptation and gives the body a clean baseline between phases.

Typical cycle structure:

• Weeks 1-2: Ramp from 250 mcg/day to 250 mcg twice daily
• Weeks 3-10: Maintenance at chosen dose (250-500 mcg twice daily)
• Weeks 11-12: Optional taper
• Washout: 4-8 weeks fully off before any subsequent cycle

Track skinfold, waist circumference, and body weight rather than the scale alone. The signal is in the composition change, not the absolute number.

Realistic Expectations

This is the most important section. The community signal around Fragment 176-191 is mixed for good reason.

• Clinical data is limited — The fragment has not progressed through large-scale human obesity trials. Most published work is animal-based or early-phase.
• Real-world results are modest — Users running well-structured protocols typically report 2-5 lbs of fat loss attributable to the peptide over 8-12 weeks, on top of dietary and training effects.
• Do not expect rapid transformation — Marketing language suggesting "targeted fat loss" or "dissolving belly fat" is unsupported.
• Mechanism does not guarantee magnitude — A peptide can plausibly stimulate lipolysis and still produce only minor downstream changes in body composition.
• AOD-9604 results are comparable — In direct comparison, neither has demonstrated dramatic superiority in published or community data.
• Individual variability is high — Two users on identical protocols may report very different outcomes; genetics, baseline body fat, training history, and adherence all matter more than the peptide itself.
• The "spot reduction" framing is misleading — While subcutaneous abdominal fat may be preferentially affected in some users, this is not a guaranteed regional effect.

Honest framing protects you from disappointment and from over-investing in a single compound when the lever that matters most is energy balance. Treat Fragment 176-191 as an optional adjunct, not as the engine of a fat-loss phase.

Frequently Asked Questions

Q: What is the difference between Fragment 176-191 and AOD-9604? A: Fragment 176-191 is the raw 16-amino-acid C-terminal piece of hGH. AOD-9604 is the same sequence with an added tyrosine and a disulfide bond engineered for improved stability. AOD has progressed further in clinical development; Frag remains earlier-stage. In practice, vendor labeling is often inconsistent between the two.

Q: Will I see real fat loss? A: Probably modest. Most users report 2-5 lbs over 8-12 weeks when paired with a caloric deficit and cardio. Without a deficit, results are typically negligible. This is not a body-recomposition shortcut.

Q: Does Fragment 176-191 spare muscle? A: There is no evidence that it builds or significantly preserves muscle. Muscle preservation in a cut depends on protein intake, resistance training, and overall deficit size — not on this peptide.

Q: Do I have to dose fasted? A: No, but most community protocols favor fasted morning dosing for mechanistic reasons (low insulin, lipolytic context). There is no controlled human trial showing fasted dosing outperforms fed dosing meaningfully.

Q: Can I stack it with semaglutide or tirzepatide? A: Mechanistically, yes — they act on different pathways. Coordinate with your prescriber, monitor for additive side effects (fatigue, GI symptoms), and remember the GLP-1 is doing most of the heavy lifting in any layered protocol.

Q: How concerned should I be about sourcing purity? A: Very. Mislabeling between Frag 176-191 and AOD-9604 is common. Demand a third-party COA with HPLC purity (>98%) and mass spectrometry confirming the correct molecular weight. Suspiciously low prices and pre-mixed solutions are red flags.

Q: Is Fragment 176-191 FDA-approved? A: No. It is sold as a research chemical and is not approved for human therapeutic use. It is also prohibited under the WADA code for competitive athletes.

Q: How long until I see results? A: Subjective changes are uncommon before week 4. Visible subcutaneous changes, when they occur, typically appear between weeks 6 and 12, and only in combination with appropriate diet and training.

Related Content

• AOD-9604 Protocol
• CJC-1295 Protocol
• GH Peptide Stacking Guide
• GH Secretagogue Protocol
• Reconstitution Cheat Sheet
• COA Reading Guide

Disclaimer: This content is for educational purposes only and is not medical advice. HGH Fragment 176-191 is a research compound and is not FDA-approved for human use. It is prohibited under the World Anti-Doping Agency (WADA) code for competitive athletes. Consult a licensed healthcare provider before starting any peptide protocol.

Source: https://peptides.nyc/learn/fragment-176-191-protocol